General Dermatology

At SBS 2026, Karan Lal, MD, and Mohammad Goldust, MD, reveal how social media and AI reshape dermatology trust and care.

Michael Gold, MD, shares insights on safer device use, peptides, GLP-1s, acne, hair therapies, and more.

As SBS kicks off in South Beach Miami, scroll through faces familiar to Dermatology Times presenting at the symposium.

La Roche-Posay and the Oncology Nursing Society mark World Cancer Day with a first-of-its-kind tool, improving cancer care in patients with skin of color.

Clinicians assess chronic urticaria prevalence and impact, revealing gaps in understanding and treatment that affect patient care and outcomes.

Explore innovative treatments for skin conditions, including lebrikizumab for pemphigus and low-level laser therapy for hair loss.

James Del Rosso, DO, discusses diagnosis and treatment of mastocytosis and inflammatory conditions.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news on the FDA's breakthrough designation of litifilimab for CLE, data on bitopertin in EPP treatment, the role of icotrokinra in the psoriasis landscape, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Dermatology Times is looking back on the top stories in dermatology from the month of January.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

Galderma addresses menopause-related skin changes at IMCAS 2026, revealing survey insights and committing to inclusive clinical trials for better patient solutions.

Learn more about the in-depth topics covered in the January 2026 print issue of Dermatology Times.

Dermatology Times is recapping our exclusive expert interviews from the month of January.

James Del Rosso, DO, discusses innovative therapies for chronic hand eczema (CHE), chronic spontaneous urticaria (CSU), and vitiligo.

Explore the nuances of off-label dermatology therapies, emphasizing evidence-based practices, patient communication, and ethical considerations for optimal care.

Litifilimab shows significant efficacy in improving skin outcomes for CLE, as demonstrated in the phase 2 LILAC study.

Explore the potential of glucagon-like peptide-1 (GLP-1) therapies in dermatology, including inflammatory skin diseases such as psoriasis and hidradenitis suppurativa, to improve patient outcomes.

Bitopertin shows promise as a disease-modifying therapy for erythropoietic protoporphyria, significantly reducing PPIX levels and improving patient outcomes.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news on phase 3 delgocitinib in lichen sclerosus, amlitelimab's every-12-week dosing in AD, Galderma's phase 3 aesthetics data, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Explore the transformative role of AI in dermatology with Nawar Shara, PhD, focusing on personalized skin care and patient safety.

Belimumab shows significant long-term benefits for cutaneous lupus erythematosus, improving skin symptoms and maintaining efficacy.